The recovery percentages of IP/INPUT, indicating the binding of c-Myc to the Sp1 was exposure time-dependently reduced on the CD26 promoter of myeloma cells on treatment with each HDACi (Fig. 5E). This evidence concerns the gene MYC and plasma cell myeloma.